Knee replacement alternatives work best when the care fits you

Steady exercise can make standing and walking easier

Stronger leg muscles can steady your knee on stairs and help you rise from a chair, as long as the exercise suits your balance, strength, and present soreness. It shouldn’t feel like a test of will. A physical therapist can change an exercise when the knee objects. If carrying extra weight strains the joint, a modest loss may ease some of the load.

You’re welcome to begin gently.

Medicine rubbed on the knee, a cane, or a brace may help

Topical medicine is put directly on your knee, usually as a cream or gel. Because it stays near the joint, it may affect other parts of your body less than a pill. Tablets can help too, but kidney, heart, or stomach problems may narrow the safe choices. Using a cane or wearing a brace that fits can ease strain during daily tasks. Your doctor can help match each choice to your health.

More medicine isn’t always kinder care.

Steroid procedures, PRP, and surgery need a talk with your doctor

A steroid procedure may ease soreness for weeks or a few months. PRP is short for platelet-rich plasma, prepared by drawing your blood and spinning the sample to collect its platelets. A trained provider returns this concentrated part to the sore knee. Some reports found relief after PRP, while a large careful test found no clear gain over salt water. No knee procedure can assure you that surgery will never be needed. If daily life stays badly limited, a surgeon can explain replacement, its risks, and recovery.

Hearing those facts doesn’t commit you to an operation.

Sources

1. OARSI 2019 designates arthritis education plus structured land-based exercise (with or without dietary weight management) as CORE treatments for knee OA, and education plus structured land-based exercise as core for hip and polyarticular OA. Topical NSAIDs are strongly recommended for knee OA (Level 1A). Intra-articular corticosteroids and hyaluronic acid are Level 1B/2 for knee OA depending on comorbidity and are NOT recommended for hip or polyarticular OA. Oral NSAIDs are not recommended for people with cardiovascular comorbidity or frailty, and oral and transdermal opioids are strongly not recommended (Level 5).

   Bannuru RR, Osani MC, Vaysbrot EE, et al. — OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis.. Osteoarthritis and Cartilage, 2019. DOI: 10.1016/j.joca.2019.06.011.

2. The 2019 ACR/Arthritis Foundation guideline makes STRONG recommendations for exercise, weight loss in people with knee and/or hip OA who are overweight or obese, self-efficacy and self-management programs, tai chi, cane use, tibiofemoral bracing for tibiofemoral knee OA, topical NSAIDs for knee OA, oral NSAIDs, and intra-articular glucocorticoid injections for knee OA. Radiofrequency ablation for knee OA, acupuncture, thermal modalities, acetaminophen, duloxetine and tramadol are only CONDITIONAL recommendations.

   Kolasinski SL, Neogi T, Hochberg MC, et al. — 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee.. Arthritis & Rheumatology, 2020. DOI: 10.1002/art.41142.

3. The Cochrane review of topical NSAIDs for chronic musculoskeletal pain in adults evaluated randomised, double-blind, placebo- or active-controlled trials meeting stringent quality criteria, searched to February 2016, and is the evidence base underlying the guideline preference for topical over oral NSAIDs in knee osteoarthritis.

   Derry S, Conaghan P, Da Silva JA, et al. — Topical NSAIDs for chronic musculoskeletal pain in adults.. Cochrane Database of Systematic Reviews, 2016. DOI: 10.1002/14651858.CD007400.pub3.

4. A Bayesian network meta-analysis of 137 randomised trials (33,243 participants) comparing acetaminophen, diclofenac, ibuprofen, naproxen, celecoxib, intra-articular corticosteroids, intra-articular hyaluronic acid and oral and intra-articular placebo for knee OA found all interventions significantly better than oral placebo for pain, with effect sizes ranging from 0.63 (95% CrI 0.39 to 0.88) for hyaluronic acid down to 0.18 (0.04 to 0.33) for acetaminophen at 3-month follow-up. For function, all interventions except intra-articular corticosteroids beat oral placebo.

   Bannuru RR, Schmid CH, Kent DM, et al. — Comparative effectiveness of pharmacologic interventions for knee osteoarthritis: a systematic review and network meta-analysis.. Annals of Internal Medicine, 2015. DOI: 10.7326/M14-1231.

5. A meta-analysis of 10 randomised trials (739 patients) of valgus knee bracing for knee osteoarthritis found no statistically significant effect on VAS pain (RR -0.29, 95% CI -0.73 to 0.15, P=0.20), WOMAC function (RR -0.15, 95% CI -0.41 to 0.11, P=0.26) or KOOS, concluding that valgus bracing may have no long-term effect on pain improvement or functional activity.

   Fan Y, Li Z, Zhang H, et al. — Valgus knee bracing may have no long-term effect on pain improvement and functional activity in patients with knee osteoarthritis: a meta-analysis of randomized trials.. Journal of Orthopaedic Surgery and Research, 2020. DOI: 10.1186/s13018-020-01917-x.

6. The RESTORE trial randomised 288 community-based participants aged 50+ with symptomatic medial knee OA (Kellgren-Lawrence grade 2 or 3) to three weekly intra-articular injections of leukocyte-poor PRP or saline placebo, with participants, injectors and assessors all blinded. 93% completed the 12-month follow-up. PRP did not produce a clinically meaningful improvement in knee pain over placebo, and did not slow medial tibial cartilage volume loss on MRI.

   Bennell KL, Paterson KL, Metcalf BR, et al. — Effect of Intra-articular Platelet-Rich Plasma vs Placebo Injection on Pain and Medial Tibial Cartilage Volume in Patients With Knee Osteoarthritis: The RESTORE Randomized Clinical Trial.. JAMA, 2021. DOI: 10.1001/jama.2021.19415.

7. A meta-analysis of 16 randomised trials (807 participants) of intra-articular mesenchymal stem cells for chronic knee pain from osteoarthritis found that at 3-6 months MSC therapy probably produces little to no difference in pain (WMD -0.74cm on a 10cm VAS, 95% CI -1.16 to -0.33, against a minimally important difference of 1.5cm) or physical function, both moderate certainty; at 12 months, probably little to no difference in pain. MSC therapy may increase the risk of any adverse event (RR 2.67, 95% CI 1.19 to 5.99) and of knee pain and swelling (RR 1.58, 95% CI 1.04 to 2.38).

   Sadeghirad B, Rehman Y, Khosravirad A, et al. — Mesenchymal stem cells for chronic knee pain secondary to osteoarthritis: A systematic review and meta-analysis of randomized trials.. Osteoarthritis and Cartilage, 2024. DOI: 10.1016/j.joca.2024.04.021.

8. In the only randomised controlled trial to compare total knee replacement directly with non-surgical treatment in patients already eligible for surgery (n=100), the replacement group improved more at 12 months than the non-surgical group (KOOS4 32.5 vs 16.0; adjusted mean difference 15.8, 95% CI 10.0 to 21.5) but had four times the serious adverse events (24 vs 6, P=0.005). Only 13 of 50 patients (26%) assigned to non-surgical treatment alone had undergone knee replacement by 12 months.

   Skou ST, Roos EM, Laursen MB, et al. — A Randomized, Controlled Trial of Total Knee Replacement.. New England Journal of Medicine, 2015. DOI: 10.1056/NEJMoa1505467.

9. At 2 years across two parallel randomised trials (200 patients, mean age 66), total knee replacement plus non-surgical treatment beat non-surgical treatment alone by 18.3 KOOS points (95% CI 11.3 to 25.3), and non-surgical treatment in turn beat written advice by 7.0 points (95% CI 0.4 to 13.5). Among patients eligible for replacement, 16 of 50 (32%) in the non-surgical group had surgery within 2 years - meaning two out of three delayed it for at least two years.

   Skou ST, Roos EM, Laursen MB, et al. — Total knee replacement and non-surgical treatment of knee osteoarthritis: 2-year outcome from two parallel randomized controlled trials.. Osteoarthritis and Cartilage, 2018. DOI: 10.1016/j.joca.2018.04.014.

10. A 2026 network meta-analysis of 21 RCTs (2,254 patients) found both leukocyte-poor and leukocyte-rich PRP significantly improved 6-12 month WOMAC function versus placebo (MD -10.54 and -13.20 respectively) and both were superior to hyaluronic acid, with leukocyte-poor PRP ranked first (P-score 0.96) — a materially more favourable read of PRP than the RESTORE trial, which is why this corpus presents both.

    Journal of Orthopaedic Surgery and Research authors — Leukocyte-rich versus leukocyte-poor platelet-rich plasma and hyaluronic acid for knee osteoarthritis: a systematic review and network meta-analysis.. Journal of Orthopaedic Surgery and Research, 2026. DOI: 10.1186/s13018-026-06689-4.